Loading...

IDEXX OPTI Medical

OPTI Medical Systems, a subsidiary of IDEXX Laboratories, Inc., is an international and fast-growing diagnostics business with operations in Atlanta, Georgia, USA, serving the high-growth, near-patient testing market, targeting small- to medium-sized hospitals. The portable OPTI product line of blood gas analyzers first came to the U.S. healthcare market in 1995 under the name of AVL Medical Instruments, a leader in blood gas analyzers since 1967. Since then, the OPTI product line has established market positions throughout the world with an existing customer base of over 10,000 instruments already in use. OPTI Medical’s established operational infrastructure and strong international distributor network support its worldwide sales.

About IDEXX

IDEXX was incorporated in Delaware in 1983. We develop, manufacture, and distribute products and provide services primarily for the companion animal veterinary, livestock and poultry, dairy and water testing markets. We also sell a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market. Our primary products and services are:

IDEXX operates primarily through three business segments:

OPTI SARS-CoV-2 RT-PCR Test

OPTI Medical Systems has received US FDA Emergency Use Authorization and CE mark for its OPTI SARS-CoV-2 RT-PCR Test for detection of the virus causing COVID-19.
The OPTI SARS-CoV-2 RT-PCR Test is based on real-time reverse transcription polymerase chain reaction (RT-PCR), which provides detection of the viral RNA in the sample. The test can be used on both individual samples as well as in pools of 5 samples for screening purposes. It is designed for the detection of SARS-CoV-2 RNA extracted from nasopharyngeal swabs, oropharyngeal swabs and other
upper respiratory sample types.

OPTI SARS-CoV-2 Total Antibody Test

OPTI Medical Systems has received US FDA Emergency Use Authorization and CE mark for its OPTI SARS-CoV-2 RT-PCR Test for detection of the virus causing COVID-19.

The OPTI SARS-CoV-2 RT-PCR Test is based on real-time reverse transcription polymerase chain reaction (RT-PCR), which provides detection of the viral RNA in the sample. The test can be used on both individual samples as well as in pools of 5 samples for screening purposes. It is designed for the detection of SARS-CoV-2 RNA extracted from nasopharyngeal swabs, oropharyngeal swabs and other upper respiratory sample types.

A complete serology-based testing solution

Performance

Performance of the OPTI SARS-COV-2 Total Antibody Test was validated extensively using a large sample set. Results demonstrated diagnostic sensitivity of 96.1% (n = 155) ≥ 15 days after symptom onset and 96.8% (n = 201) ≥ 15 days after PCR-positive result. The diagnostic specificity of the test was 98.0% (n = 405).
IDEXX Laboratories, the parent of OPTI Medical Systems, has extensive expertise in ELISA development and manufacturing.

Mic-4 qPCR Cycler

Portable and compact—our 4-channel qPCR instrument runs up to 48 samples at a time.

Accurate and more reliable—no instrument calibration required

The Mic qPCR Cycler utilizes a unique spinning aluminum rotor which ensures even temperature
distribution across samples so no calibration requirements are neccessary. This produces more accurate results in comparison to other block-based cyclers that are not heated and cooled consistently which can cause greater variability across the block.

Plug and play

Technical advancements in performance